

Title (en)
COMBINATION THERAPY FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES

Title (de)
KOMBINATIONSTHERAPIE ZUR MODULIERUNG VON GALLENÄUREHOMÖOSTASE UND BEHANDLUNG VON
GALLENÄURESTÖRUNGEN UND -ERKRANKUNGEN

Title (fr)
POLYTHÉRAPIE POUR LA MODULATION DE L'HOMÉOSTASIE DE L'ACIDE BILIAIRE ET LE TRAITEMENT DES TROUBLES ET DE
MALADIES DE L'ACIDE BILIAIRE

Publication
EP 3955954 A1 20220223 (EN)

Application
EP 20791431 A 20200416

Priority
• US 201962835340 P 20190417
• US 2020028413 W 20200416

Abstract (en)
[origin: WO2020214753A1] Provided herein are methods of modulating bile acid homeostasis or treating a bile acid-related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile acid-related or associated disorder.

IPC 8 full level
A61K 38/18 (2006.01); **C07K 14/50** (2006.01); **G01N 33/50** (2006.01); **G01N 33/68** (2006.01)

CPC (source: EP US)
A61K 31/05 (2013.01 - EP); **A61K 31/155** (2013.01 - EP); **A61K 31/192** (2013.01 - EP); **A61K 31/195** (2013.01 - EP);
A61K 31/216 (2013.01 - EP); **A61K 31/366** (2013.01 - EP); **A61K 31/40** (2013.01 - EP); **A61K 31/403** (2013.01 - EP);
A61K 31/4439 (2013.01 - EP); **A61K 31/497** (2013.01 - EP); **A61K 31/4985** (2013.01 - EP); **A61K 31/513** (2013.01 - EP);
A61K 31/522 (2013.01 - EP); **A61K 35/28** (2013.01 - EP); **A61K 38/1825** (2013.01 - EP US); **A61K 38/2264** (2013.01 - EP);
A61K 38/26 (2013.01 - EP); **A61K 38/28** (2013.01 - EP); **A61P 1/00** (2017.12 - US); **A61P 1/12** (2017.12 - EP); **A61P 1/16** (2017.12 - EP);
A61P 3/00 (2017.12 - EP); **A61P 3/06** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **C07K 14/50** (2013.01 - EP)

C-Set (source: EP)
1. **A61K 38/26 + A61K 2300/00**
2. **A61K 31/522 + A61K 2300/00**
3. **A61K 31/4439 + A61K 2300/00**
4. **A61K 31/192 + A61K 2300/00**
5. **A61K 31/195 + A61K 2300/00**
6. **A61K 31/216 + A61K 2300/00**
7. **A61K 31/366 + A61K 2300/00**
8. **A61K 31/155 + A61K 2300/00**
9. **A61K 31/05 + A61K 2300/00**
10. **A61K 31/497 + A61K 2300/00**
11. **A61K 38/1825 + A61K 2300/00**
12. **A61K 38/28 + A61K 2300/00**
13. **A61K 38/2264 + A61K 2300/00**
14. **A61K 35/28 + A61K 2300/00**
15. **A61K 31/4985 + A61K 2300/00**
16. **A61K 31/40 + A61K 2300/00**
17. **A61K 31/513 + A61K 2300/00**
18. **A61K 31/403 + A61K 2300/00**

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2020214753 A1 20201022; AU 2020260110 A1 20211111; CA 3137028 A1 20201022; EP 3955954 A1 20220223; EP 3955954 A4 20230517;
US 2020390858 A1 20201217

DOCDB simple family (application)
US 2020028413 W 20200416; AU 2020260110 A 20200416; CA 3137028 A 20200416; EP 20791431 A 20200416;
US 202016850818 A 20200416